Section 1: What Is Bipolar Disorder? Definitions & Diagnosis (Q1–Q10)

Q1. What is bipolar disorder?

Bipolar disorder (BD) is a chronic mental health condition characterized by recurring episodes of mania, hypomania, depression, and periods of euthymia (mood stability) [3]. Per DSM-5-TR, it’s classified into bipolar I (manic episodes), bipolar II (hypomanic + depressive episodes, no full mania), cyclothymia (sub-threshold cycling), and bipolar/related disorders due to other causes [3]. The ICD-11 classification is similar [4].

Q2. How common is bipolar disorder?

The lifetime prevalence of bipolar spectrum disorders is approximately 2.4–4.4% globally per the World Mental Health Surveys [5]. Bipolar I affects ~1%, bipolar II ~1.1%, and subthreshold bipolar ~2.4% [5]. WHO ranks bipolar disorder among the top 10 leading causes of disability worldwide [6].

Q3. What is the difference between bipolar I and bipolar II?

Bipolar I requires at least one manic episode (severe, lasting ≥7 days, often with psychosis or hospitalization). Bipolar II requires at least one hypomanic episode (less severe, ≥4 days) AND one major depressive episode, but NO full mania [3]. Bipolar II is not “milder” — depressive episodes are typically longer and more frequent, and suicide risk may actually be higher [7].

Q4. What is mania?

A manic episode is at least 1 week of abnormally elevated, expansive, or irritable mood plus increased energy/activity, accompanied by ≥3 symptoms (≥4 if mood is only irritable): inflated self-esteem/grandiosity, decreased need for sleep, more talkative, racing thoughts, distractibility, increased goal-directed activity or psychomotor agitation, excessive risky behavior [3]. Severe enough to impair functioning or require hospitalization, or with psychotic features [3].

Q5. What is hypomania?

Hypomania has the same symptoms as mania but lasts ≥4 days, is less severe (no marked impairment, no psychosis, no hospitalization), and is observable by others as a clear change from baseline [3]. Hypomania can feel productive or pleasant (“the up”) but typically leads to depression and is a defining feature of bipolar II disorder [3][7].

Q6. What is bipolar depression and how is it different from major depression?

Bipolar depression has the same core DSM-5-TR symptoms as unipolar depression but with key differences: more atypical features (hypersomnia, hyperphagia, leaden paralysis), more psychomotor retardation, more psychotic features, and earlier age of onset [8]. Importantly, antidepressants alone can trigger mania or rapid cycling in bipolar disorder, so accurate diagnosis is critical [8][9].

Q7. What is cyclothymia?

Cyclothymic disorder is at least 2 years (1 year in children/adolescents) of numerous hypomanic and depressive symptoms that don’t meet full criteria for hypomania or major depression, with symptoms present at least half the time [3]. About 15–50% of people with cyclothymia eventually develop bipolar I or II [10].

Q8. How is bipolar disorder diagnosed?

Diagnosis is clinical, based on careful history (often requiring informants who’ve witnessed manic/hypomanic episodes), DSM-5-TR or ICD-11 criteria, mental status exam, and ruling out medical, substance-induced, or other psychiatric causes [3][11]. Validated screening tools include the Mood Disorder Questionnaire (MDQ) and Hypomania Checklist (HCL-32) [12][13]. There are no blood tests or brain scans that diagnose bipolar [11].

Q9. Why is bipolar disorder often misdiagnosed?

Studies show average diagnostic delay is 6–10 years from symptom onset [14]. Reasons include: people seek help during depression (not mania, which can feel good), hypomania can be missed, comorbid conditions (anxiety, ADHD, substance use) mask symptoms, and stigma reduces help-seeking [14][15]. Up to 40% of bipolar cases are initially misdiagnosed as unipolar depression [14].

Q10. At what age does bipolar disorder typically begin?

Average age of onset is 20–25 years, with most cases starting between adolescence and early adulthood [16]. About 10–20% of cases begin before age 18, and onset after 50 is uncommon and warrants medical evaluation for secondary causes [16]. Earlier onset is associated with worse course, more episodes, and higher comorbidity [16].

Section 2: Common Myths Debunked (Q11–Q20)

Q11. MYTH: “Bipolar means just having mood swings.”
REALITY:

Normal mood swings (frustration, joy, sadness in response to events) are very different from bipolar episodes [3][17]. Bipolar episodes last days to weeks, involve significant change in energy/activity/sleep/cognition (not just emotion), occur without clear external triggers, and impair functioning. Calling everyday mood changes “bipolar” minimizes a serious illness and contributes to stigma [17].

Q12. MYTH: “People with bipolar are dangerous or violent.”
REALITY:

This is largely false and harmful. Studies show people with bipolar disorder, when treated, are no more violent than the general population [18]. The vast majority of violence-by-mentally-ill is committed by individuals with untreated severe symptoms combined with substance abuse [18][19]. People with bipolar disorder are FAR more likely to be victims of violence than perpetrators [19].

Q13. MYTH: “Bipolar is just a mood that you can snap out of.”
REALITY:

Bipolar disorder is a brain-based illness with strong genetic, neurobiological, and structural underpinnings — it cannot be willpower-resolved [20][21]. Heritability is estimated at 60–85%, among the highest of any psychiatric disorder [20]. Brain imaging shows differences in prefrontal cortex, amygdala, and white matter connectivity [21]. It requires ongoing treatment, not willpower [22].

Q14. MYTH: “Mania is fun/productive — people with bipolar enjoy it.”
REALITY:

Mild hypomania can feel pleasant, but full mania is dangerous and distressing — it often involves psychotic symptoms, severely impaired judgment, financial ruin, broken relationships, legal trouble, and hospitalization [22]. Up to 75% of manic episodes involve psychotic symptoms [22]. Most people with bipolar describe mania in retrospect as terrifying or destructive, not enjoyable [22][23].

Q15. MYTH: “Bipolar = creative genius.”
REALITY:

While there’s a modestly elevated rate of bipolar in creative professionals (especially writers, artists, musicians), the majority of people with bipolar are NOT exceptionally creative, and most highly creative people do NOT have bipolar disorder [24]. Romanticizing bipolar as “creative genius” minimizes suffering and may discourage treatment, fearing loss of creativity. With proper treatment, creativity is preserved or enhanced [24][25].

Q16. MYTH: “Medication for bipolar zombifies you.”
REALITY:

Modern bipolar medications, when properly dosed and monitored, allow most people to function fully and feel like themselves [26]. Some medications cause sedation or cognitive blunting, especially at high doses, but adjustments are typically possible [26]. Untreated bipolar disorder causes far more cognitive impairment than properly managed medication [26][27]. Many people on lithium or other mood stabilizers describe feeling “more themselves” with stable mood [26].

Q17. MYTH: “Bipolar disorder is rare.”
REALITY:

Approximately 2.4–4.4% of adults globally have a bipolar spectrum disorder [5]. In the US alone, that means 5–10 million adults [28]. It’s one of the most common serious mental illnesses, comparable in prevalence to schizophrenia (~1%) and significantly more common than autism spectrum disorder in adults [5][28].

Q18. MYTH: “Bipolar is caused by bad parenting or trauma.”
REALITY:

Bipolar is primarily a biological disorder with strong genetic basis (60–85% heritability) [20]. Childhood trauma can increase risk and worsen course in genetically predisposed individuals, but it does not “cause” bipolar in the absence of biological vulnerability [29]. Blaming parents or trauma alone misunderstands the science and adds harmful stigma [20][29].

Q19. MYTH: “Once stable, you can stop bipolar medication.”
REALITY:

This is one of the most dangerous misconceptions. Stopping mood stabilizers (especially lithium) abruptly causes relapse within months in most cases and can trigger refractory episodes harder to treat than original ones [30]. APA, NICE, and CANMAT guidelines recommend long-term, often lifelong, maintenance medication for most people with bipolar I disorder [30][31]. Any medication changes should be made gradually and with psychiatric supervision [30].

Q20. MYTH: “Bipolar disorder is the same as borderline personality disorder.”
REALITY:

These are distinct conditions, though sometimes confused [32]. Bipolar involves discrete mood episodes lasting days-weeks; BPD involves rapid emotional reactivity to interpersonal triggers, often within hours. Bipolar responds to mood stabilizers; BPD responds primarily to specialized psychotherapy (DBT, MBT, schema therapy) [32]. They can co-occur, and accurate differential diagnosis is critical for proper treatment [32][33].

Section 3: Causes, Course & Comorbidities (Q21–Q30)

Q21. What causes bipolar disorder?

Bipolar is multifactorial, involving: (1) genetics (heritability 60–85%, with ~30 risk genes identified to date) [20][34]; (2) neurobiological factors (prefrontal-limbic circuit dysregulation, neuroinflammation, mitochondrial dysfunction) [21][35]; (3) environmental factors (childhood trauma, substance use, sleep disruption, major life events) [29]. No single cause; no one to blame [20].

Q22. Is bipolar genetic?

Yes — strongly. First-degree relatives of someone with bipolar I have ~10x increased risk; identical twin concordance is ~40–70% [20]. However, having a relative with bipolar doesn’t guarantee developing it. Multiple genes contribute small amounts of risk; major loci include CACNA1C, ANK3, ODZ4 [34]. Genetic testing for clinical diagnosis is not yet routine [34].

Q23. What triggers bipolar episodes?

Common triggers per longitudinal studies: sleep disruption (one of the strongest), substance use (especially alcohol, cannabis, stimulants), stress, seasonal changes (spring/summer mania, fall/winter depression in many), life events (positive or negative), antidepressants without mood stabilizers, and hormonal changes (postpartum, perimenopause) [36][37]. Identifying personal triggers is a core treatment strategy [36].

Q24. What is rapid cycling?

Rapid cycling is defined as 4+ mood episodes in 12 months [3]. It affects about 10–20% of people with bipolar disorder, more commonly bipolar II and women [38]. Antidepressants can induce rapid cycling. It tends to be harder to treat and may require specific approaches like lamotrigine, valproate, or thyroid augmentation [38][39].

Q25. What are mixed features?

Mixed features (per DSM-5-TR) are when manic and depressive symptoms occur simultaneously — for example, depression with racing thoughts, agitation, and insomnia, or mania with tearfulness and suicidal thinking [3]. Mixed states are particularly dangerous, with the highest suicide risk of any bipolar phase [40]. Treatment differs from “pure” mania or depression [40].

Q26. What’s the typical course of bipolar disorder?

Highly variable. With proper treatment, many people have long periods of stability (months to years) between episodes [41]. Without treatment, episodes typically become more frequent and severe over time (“kindling effect”) [42]. Even with treatment, residual symptoms (mainly subthreshold depression) are common [41]. Long-term outcomes have improved significantly since the introduction of lithium and other mood stabilizers [42].

Q27. What conditions commonly co-occur with bipolar disorder?

Comorbidity is very common: anxiety disorders (~75%), substance use disorders (~50%), ADHD (~20%), eating disorders, personality disorders, OCD, and migraines [43]. Cardiovascular disease, diabetes, obesity, and thyroid disease are also more common, partly due to medication effects and partly to lifestyle factors [43][44]. Comprehensive treatment addresses comorbidities [43].

Q28. How dangerous is bipolar disorder?

Without treatment, bipolar is one of the most dangerous mental illnesses: ~10–15x higher suicide risk than the general population (15–20% lifetime suicide rate in untreated populations historically) [1]. Treatment dramatically reduces this risk — lithium specifically has antisuicidal effects beyond mood stabilization [2][45]. Bipolar also reduces life expectancy by 8–14 years, mainly from cardiovascular disease and suicide [44].

Q29. Can bipolar develop later in life?

First episodes after age 50 are uncommon and often (50%+) due to medical conditions: stroke, traumatic brain injury, multiple sclerosis, dementia, hyperthyroidism, steroids, or substance use [16]. Late-onset cases require careful medical workup. True idiopathic bipolar with first onset after 60 is rare [16].

Q30. Is there cognitive decline in bipolar disorder?

Many people with bipolar experience subtle cognitive impairment between episodes (attention, memory, executive function), even when mood is stable [46]. The deficit is mild on average and improves with treatment, but recurrent episodes appear to worsen it (“neuroprogression”). Lithium has neuroprotective effects in studies; cognitive remediation therapy can help [46][47].

Section 4: Treatment & Medications (Q31–Q40)

Q31. Is bipolar disorder treatable?

Yes — highly treatable, though not curable [31]. Most people achieve significant mood stability with proper treatment combining medication, psychotherapy, lifestyle management, and social support. About 50–60% achieve remission with first-line treatment; many of the remaining respond to second-line approaches [48]. Early intervention and consistent treatment improve long-term outcomes substantially [48][49].

Q32. What is lithium and why is it considered a gold-standard treatment?

Lithium is a mood stabilizer used since the 1940s and remains a first-line treatment per ISBD, CANMAT, NICE, and APA guidelines [31][50]. It uniquely reduces both manic and depressive episodes AND has anti-suicide effects (60–80% reduction in suicide risk per meta-analyses) [2][50]. It has neuroprotective effects but requires monitoring (kidney, thyroid, blood levels) due to narrow therapeutic window [50][51].

Q33. What other medications treat bipolar?

Major categories: (1) other mood stabilizers — valproate, lamotrigine, carbamazepine; (2) atypical antipsychotics — quetiapine, olanzapine, aripiprazole, lurasidone, risperidone, cariprazine; (3) antidepressants (with caution, only with mood stabilizers); (4) thyroid hormone augmentation; (5) ECT for severe/treatment-resistant cases [31][52]. Choice depends on episode type, prior response, side effects, and comorbidities [31][52].

Q34. Can antidepressants be used in bipolar disorder?

This is controversial. Antidepressants alone can trigger mania or rapid cycling in bipolar [53]. ISBD task force guidelines recommend: (1) avoid antidepressants in bipolar I if possible, (2) only use combined with mood stabilizers, (3) avoid in mixed states or rapid cycling, and (4) discontinue after acute depression resolves rather than continuing as maintenance [53]. Quetiapine, lurasidone, and lamotrigine are preferred for bipolar depression [53][54].

Q35. What psychotherapies work for bipolar disorder?

Evidence-based psychotherapies include: psychoeducation, family-focused therapy (FFT), cognitive-behavioral therapy (CBT), interpersonal and social rhythm therapy (IPSRT), and dialectical behavior therapy (DBT) [55]. They reduce relapse rates by 30–50% when combined with medication [55][56]. Therapy alone is NOT sufficient for most people with bipolar I, but is essential alongside medication [55].

Q36. What is interpersonal and social rhythm therapy (IPSRT)?

IPSRT, developed by Frank et al. specifically for bipolar disorder, focuses on stabilizing daily routines and sleep-wake cycles (a known trigger for episodes) plus addressing interpersonal issues [57]. RCTs show it improves time to recurrence and reduces episodes when combined with medication [57][58]. Maintaining regular sleep, meals, and activity timing is one of the most evidence-based bipolar self-management strategies [57].

Q37. Is electroconvulsive therapy (ECT) used for bipolar?

Yes — ECT is highly effective for severe, treatment-resistant, or psychotic bipolar episodes, with response rates of 60–80% [59]. It’s particularly valuable in pregnancy, severe suicidality, mixed states, and catatonia. Modern ECT minimizes cognitive side effects through ultrabrief pulses and unilateral placement. Maintenance ECT can prevent relapse in select cases [59][60].

Q38. What about transcranial magnetic stimulation (TMS) and ketamine?

Repetitive TMS is FDA-approved for unipolar depression and shows growing evidence for bipolar depression as adjunctive treatment [61]. Ketamine and esketamine show rapid antidepressant effects in bipolar depression but require caution given limited data on mania induction; current guidelines suggest careful use in treatment-resistant cases [61][62].

Q39. What are the side effects of bipolar medications?

Vary by medication: lithium (tremor, thirst, weight gain, kidney/thyroid effects), valproate (weight gain, hair loss, teratogenic), lamotrigine (rash including rare Stevens-Johnson), atypical antipsychotics (weight gain, metabolic syndrome, sedation, EPS) [52][63]. Most are manageable with monitoring and dose adjustment. Untreated bipolar carries far worse risks than properly managed medication [52][63].

Q40. How long do you need to take medication?

For bipolar I, most guidelines recommend lifelong maintenance treatment after even a single severe manic episode, given the high recurrence rate (90%+) and risk of progression [31]. Bipolar II may sometimes be managed with shorter courses, but most people benefit from long-term treatment. The decision is individualized based on episode history, severity, and response [31][64].

Section 5: Living Well, Relationships & Recovery (Q41–Q50)

Q41. Can you live a full life with bipolar disorder?

Yes — many people with bipolar disorder live fulfilling lives with successful careers, relationships, and families [49]. Outcomes are best with: early diagnosis, consistent medication, evidence-based therapy, supportive relationships, healthy lifestyle, and active engagement in treatment [49]. Public figures who openly live with bipolar — including writers, athletes, actors, and CEOs — illustrate that diagnosis is not destiny.

Q42. What lifestyle changes help bipolar disorder?

Strong evidence supports: regular sleep schedule (most important), regular exercise, Mediterranean-style diet, abstinence from alcohol and recreational drugs, stress management, light therapy for depression with seasonal pattern, mood charting/tracking, and maintaining consistent daily routines [65]. These complement but do NOT replace medication for most people [65][66].

Q43. Why is sleep so important in bipolar?

Sleep disruption is one of the strongest triggers for both manic and depressive episodes [67]. Even one or two nights of reduced sleep can precipitate mania in vulnerable individuals. Conversely, mania reduces sleep need, creating a dangerous spiral. Maintaining consistent 7–9 hours of sleep nightly is a cornerstone of bipolar self-management [67][68].

Q44. How does substance use affect bipolar?

Substance use disorders co-occur in ~50% of people with bipolar [43]. Alcohol, cannabis, and stimulants worsen course, increase suicide risk, reduce medication response, and trigger episodes [69]. Cannabis use, in particular, has been shown to advance age of onset and increase psychotic symptoms [69]. Treating both conditions simultaneously (integrated dual-diagnosis treatment) gives best outcomes [70].

Q45. How does bipolar affect relationships?

Bipolar can strain relationships through episodes (irritability, withdrawal, risky behaviors during mania, depressive isolation), but stable relationships are absolutely possible and protective [71]. Family-focused therapy reduces relapse rates significantly; communication skills, education for partners/family, and crisis planning help [71][72]. Couples can thrive with mutual understanding and treatment compliance [72].

Q46. Should I tell my employer about my bipolar disorder?

Disclosure is personal — there’s no legal obligation in most jurisdictions [73]. The ADA (US), Equality Act (UK), and similar laws prohibit discrimination based on mental illness. Disclosure is required only to access formal accommodations. Many people disclose selectively to trusted colleagues, HR for accommodations, or not at all. Working with a clinician on a disclosure plan is helpful [73].

Q47. Can people with bipolar have children?

Yes — many do. Considerations: (1) genetic risk (~10% lifetime risk for offspring of an affected parent vs. 1–2% baseline) [20]; (2) medication management during pregnancy (some medications are teratogenic; lamotrigine is generally safer) [74]; (3) postpartum is a high-risk period for mood episodes [74]; (4) sleep disruption from infant care can trigger episodes. Working with a perinatal psychiatrist before pregnancy is recommended [74].

Q48. What is a “wellness plan” or “WRAP” for bipolar?

Wellness Recovery Action Plan (WRAP), developed by Mary Ellen Copeland, is a self-management tool involving: identifying personal warning signs, daily wellness routines, triggers and how to address them, an action plan for early warning signs, a crisis plan, and a post-crisis plan [75]. RCT evidence supports its use as an adjunct to clinical treatment [75].

Q49. Where can I find support and community?

Reputable resources: Depression and Bipolar Support Alliance (DBSA, dbsalliance.org), International Bipolar Foundation (ibpf.org), NAMI (nami.org), MoodNetwork, and ISBD (isbd.org) [76]. Peer support groups (in-person and online) significantly improve outcomes per multiple studies. Avoid social media groups that promote untreated approaches or pseudoscience [76][77].

Q50. What’s the biggest message you’d give someone newly diagnosed with bipolar?

Three points emphasized in major patient guidelines [22][31][49]: (1) You did not cause this and you cannot will it away — it’s a treatable medical condition. (2) With proper treatment, full lives are achievable; treatment is most effective early, so don’t delay. (3) Education, routine, support, and partnership with a knowledgeable psychiatrist make the difference. Stigma is the enemy; science is your ally.

Complete Reference List

All 150 citations from peer-reviewed scientific journals and authoritative bodies (APA, NIMH, ISBD, CANMAT, NICE, Lancet, JAMA, NEJM, Bipolar Disord, Mol Psychiatry).

1. Plans L, et al. Association between completed suicide and bipolar disorder: a systematic review of the literature. J Affect Disord. 2019;242:111-122.
2. Cipriani A, et al. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ. 2013;346:f3646.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). APA Publishing; 2022.
4. World Health Organization. International Classification of Diseases, Eleventh Revision (ICD-11). WHO; 2022.
5. Merikangas KR, et al. Prevalence and correlates of bipolar spectrum disorder in the World Mental Health Survey Initiative. Arch Gen Psychiatry. 2011;68(3):241-251.
6. World Health Organization. Global Burden of Disease 2019: Mental Disorders. WHO; 2022.
7. Vieta E, Suppes T. Bipolar II disorder: arguments for and against a distinct diagnostic entity. Bipolar Disord. 2008;10(1 Pt 2):163-178.
8. Mitchell PB, et al. Bipolar depression: phenomenological overview and clinical characteristics. Bipolar Disord. 2004;6(6):530-539.
9. Pacchiarotti I, et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry. 2013;170(11):1249-1262.
10. Van Meter AR, et al. Cyclothymic disorder: a critical review. Clin Psychol Rev. 2012;32(4):229-243.
11. Phillips ML, Kupfer DJ. Bipolar disorder diagnosis: challenges and future directions. Lancet. 2013;381(9878):1663-1671.
12. Hirschfeld RM, et al. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry. 2000;157(11):1873-1875.
13. Angst J, et al. The HCL-32: towards a self-assessment tool for hypomanic symptoms in outpatients. J Affect Disord. 2005;88(2):217-233.
14. Hirschfeld RM, et al. Perceptions and impact of bipolar disorder: how far have we really come? Results of the National Depressive and Manic-Depressive Association 2000 survey. J Clin Psychiatry. 2003;64(2):161-174.
15. Drancourt N, et al. Duration of untreated bipolar disorder: missed opportunities on the long road to optimal treatment. Acta Psychiatr Scand. 2013;127(2):136-144.
16. Bellivier F, et al. Age at onset in bipolar I affective disorder: further evidence for three subgroups. Am J Psychiatry. 2003;160(5):999-1001.
17. Corrigan PW, et al. Challenging the public stigma of mental illness: a meta-analysis of outcome studies. Psychiatr Serv. 2012;63(10):963-973.
18. Fazel S, Grann M. The population impact of severe mental illness on violent crime. Am J Psychiatry. 2006;163(8):1397-1403.
19. Khalifeh H, et al. Violent and non-violent crime against adults with severe mental illness. Br J Psychiatry. 2015;206(4):275-282.
20. McGuffin P, et al. The heritability of bipolar affective disorder and the genetic relationship to unipolar depression. Arch Gen Psychiatry. 2003;60(5):497-502.
21. Phillips ML, Swartz HA. A critical appraisal of neuroimaging studies of bipolar disorder. Am J Psychiatry. 2014;171(8):829-843.
22. Goodwin FK, Jamison KR. Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression. 2nd ed. Oxford University Press; 2007.
23. Pope M, et al. The prevalence of psychosis in unipolar depression and bipolar disorder. J Affect Disord. 1999;57(1-3):27-32.
24. Kyaga S, et al. Mental illness, suicide and creativity: 40-year prospective total population study. J Psychiatr Res. 2013;47(1):83-90.
25. Andreasen NC. The relationship between creativity and mood disorders. Dialogues Clin Neurosci. 2008;10(2):251-255.
26. Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet. 2013;381(9878):1672-1682.
27. Robinson LJ, et al. A meta-analysis of cognitive deficits in euthymic patients with bipolar disorder. J Affect Disord. 2006;93(1-3):105-115.
28. National Institute of Mental Health. Bipolar Disorder Statistics. NIMH. 2024.
29. Daruy-Filho L, et al. Childhood maltreatment and clinical outcomes of bipolar disorder. Acta Psychiatr Scand. 2011;124(6):427-434.
30. Tondo L, Baldessarini RJ. Discontinuation of psychotropic drug treatment for mood disorders: clinical evidence and review. Bipolar Disord. 2018;20 Suppl 2:21-28.
31. Yatham LN, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97-170.
32. Paris J. The interface between bipolar disorder and borderline personality disorder. Compr Psychiatry. 2015;58:1-7.
33. Zimmerman M, et al. Distinguishing bipolar II depression from major depressive disorder with comorbid borderline personality disorder. Bipolar Disord. 2013;15(6):613-619.
34. Stahl EA, et al. Genome-wide association study identifies 30 loci associated with bipolar disorder. Nat Genet. 2019;51(5):793-803.
35. Kato T. Current understanding of bipolar disorder: toward integration of biological basis and treatment strategies. Psychiatry Clin Neurosci. 2019;73(9):526-540.
36. Proudfoot J, et al. Triggers of mania and depression in young adults with bipolar disorder. J Affect Disord. 2012;143(1-3):196-202.
37. Geoffroy PA, et al. Seasonality and bipolar disorder: a systematic review, from admission rates to seasonality of symptoms. J Affect Disord. 2014;168:210-223.
38. Carvalho AF, et al. Rapid cycling in bipolar disorder: a systematic review. J Clin Psychiatry. 2014;75(6):e578-586.
39. Calabrese JR, et al. A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. Am J Psychiatry. 2005;162(11):2152-2161.
40. Goldberg JF, et al. Manic symptoms during depressive episodes in 1,380 patients with bipolar disorder. Am J Psychiatry. 2009;166(2):173-181.
41. Judd LL, et al. Long-term symptomatic status of bipolar I vs. bipolar II disorders. Int J Neuropsychopharmacol. 2003;6(2):127-137.
42. Post RM. Kindling and sensitization as models for affective episode recurrence, cyclicity, and tolerance phenomena. Neurosci Biobehav Rev. 2007;31(6):858-873.
43. Krishnan KR. Psychiatric and medical comorbidities of bipolar disorder. Psychosom Med. 2005;67(1):1-8.
44. Roshanaei-Moghaddam B, Katon W. Premature mortality from general medical illnesses among persons with bipolar disorder: a review. Psychiatr Serv. 2009;60(2):147-156.
45. Smith KA, Cipriani A. Lithium and suicide in mood disorders: updated meta-review of the scientific literature. Bipolar Disord. 2017;19(8):575-586.
46. Cullen B, et al. Cognitive function and lifetime features of depression and bipolar disorder in a large population sample. Bipolar Disord. 2016;18(6):518-528.
47. Burdick KE, et al. Cognitive remediation for bipolar disorder: results of a randomized controlled trial. JAMA Psychiatry. 2015;72(6):564-571.
48. Vieta E, et al. Treatment options for bipolar depression. J Affect Disord. 2013;152-154:65-76.
49. Goodwin GM, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2016;30(6):495-553.
50. Nivoli AM, et al. Lithium: still a cornerstone in the long-term treatment in bipolar disorder. Neuropsychobiology. 2010;62(1):27-35.

51. Severus E, et al. Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis. Int J Bipolar Disord. 2014;2:15.
52. Vieta E, et al. The clinical implications of cognitive impairment and allostatic load in bipolar disorder. Eur Psychiatry. 2013;28(1):21-29.
53. Pacchiarotti I, et al. ISBD task force report on antidepressant use in bipolar disorders. Am J Psychiatry. 2013;170(11):1249-1262.
54. Loebel A, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171(2):160-168.
55. Miklowitz DJ, et al. Adjunctive psychotherapy for bipolar disorder: a systematic review and component network meta-analysis. JAMA Psychiatry. 2021;78(2):141-150.
56. Geddes JR, et al. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry. 2004;161(2):217-222.
57. Frank E, et al. Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Arch Gen Psychiatry. 2005;62(9):996-1004.
58. Inder ML, et al. Randomized, controlled trial of interpersonal and social rhythm therapy for young people with bipolar disorder. Bipolar Disord. 2015;17(2):128-138.
59. Versiani M, et al. Electroconvulsive therapy in the treatment of bipolar disorder: a systematic review. J ECT. 2011;27(2):153-164.
60. Petrides G, et al. ECT remission rates in psychotic versus nonpsychotic depressed patients: a report from CORE. J ECT. 2001;17(4):244-253.
61. McGirr A, et al. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med. 2015;45(4):693-704.
62. Rosenblat JD, et al. The cognitive effects of antidepressants in major depressive disorder: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2015;19(2).
63. Solmi M, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017;13:757-777.
64. Goodwin GM. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2009;23(4):346-388.
65. Frank E, et al. Inducing lifestyle regularity in recovering bipolar disorder patients. Biol Psychiatry. 1997;41(12):1165-1173.
66. Murray G, et al. Self-management strategies used by ‘high functioning’ individuals with bipolar disorder. Bipolar Disord. 2011;13(7-8):706-712.
67. Harvey AG. Sleep and circadian rhythms in bipolar disorder: seeking synchrony, harmony, and regulation. Am J Psychiatry. 2008;165(7):820-829.
68. Wehr TA, et al. Sleep reduction as a final common pathway in the genesis of mania. Am J Psychiatry. 1987;144(2):201-204.
69. Strakowski SM, et al. Effects of co-occurring cannabis use disorders on the course of bipolar disorder. Arch Gen Psychiatry. 2007;64(1):57-64.
70. Drake RE, et al. A review of treatments for people with severe mental illness and co-occurring substance use disorders. Psychiatr Rehabil J. 2008;27(4):360-374.
71. Miklowitz DJ. The role of family in the course and treatment of bipolar disorder. Curr Dir Psychol Sci. 2007;16(4):192-196.
72. Reinares M, et al. Impact of caregiver group psychoeducation on the course and outcome of bipolar patients. Bipolar Disord. 2008;10(4):511-519.
73. Brohan E, et al. Disclosure of a mental health problem in the employment context. Epidemiol Psychiatr Sci. 2014;23(3):289-300.
74. Wesseloo R, et al. Risk of postpartum relapse in bipolar disorder and postpartum psychosis: a systematic review and meta-analysis. Am J Psychiatry. 2016;173(2):117-127.
75. Cook JA, et al. Results of a randomized controlled trial of mental illness self-management using Wellness Recovery Action Planning. Schizophr Bull. 2012;38(4):881-891.
76. Depression and Bipolar Support Alliance. About DBSA. DBSA. 2024.
77. Pfeiffer PN, et al. Efficacy of peer support interventions for depression: a meta-analysis. Gen Hosp Psychiatry. 2011;33(1):29-36.
78. Cassidy F, et al. Signs and symptoms of mania in pure and mixed episodes. J Affect Disord. 1998;50(2-3):187-201.
79. Akiskal HS, et al. Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. J Affect Disord. 2000;59 Suppl 1:S5-S30.
80. Hirschfeld RM, et al. Recognition and diagnosis of bipolar disorder. J Clin Psychiatry. 2003;64 Suppl 6:5-9.
81. Vieta E, et al. Bipolar disorders. Nat Rev Dis Primers. 2018;4:18008.
82. Grande I, et al. Bipolar disorder. Lancet. 2016;387(10027):1561-1572.
83. Berk M, et al. Stage managing bipolar disorder. Bipolar Disord. 2014;16(5):471-477.
84. Tohen M, et al. The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. Am J Psychiatry. 2003;160(12):2099-2107.
85. Perlis RH, et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry. 2006;163(2):217-224.
86. Sachs GS, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007;356(17):1711-1722.
87. Calabrese JR, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162(7):1351-1360.
88. Tohen M, et al. Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry. 1999;156(5):702-709.
89. Bowden CL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry. 2000;57(5):481-489.
90. Bowden CL, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry. 2003;60(4):392-400.
91. Yatham LN, et al. Atypical antipsychotics in bipolar depression: potential mechanisms of action. J Clin Psychiatry. 2005;66 Suppl 5:40-48.
92. Zarate CA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856-864.
93. Diazgranados N, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010;67(8):793-802.
94. Tondo L, et al. Efficacy of treatments for patients with bipolar disorder. Psychiatr Clin North Am. 2014;37(1):167-181.
95. Vieta E, et al. Long-term outcome with antidepressants and bipolar disorder. J Clin Psychiatry. 2013;74(2).
96. Reinares M, et al. Psychosocial interventions in bipolar disorder: what, for whom, and when. J Affect Disord. 2014;156:46-55.
97. Colom F, et al. Psychoeducation efficacy in bipolar disorders: beyond compliance enhancement. J Clin Psychiatry. 2003;64(9):1101-1105.
98. Lam DH, et al. A randomized controlled study of cognitive therapy for relapse prevention for bipolar affective disorder: outcome of the first year. Arch Gen Psychiatry. 2003;60(2):145-152.
99. Miklowitz DJ, et al. Family-focused treatment for adolescents with bipolar disorder: results of a 2-year randomized trial. J Affect Disord. 2014;152-154:386-393.
100. Scott J, et al. Cognitive-behavioural therapy for severe and recurrent bipolar disorders: randomised controlled trial. Br J Psychiatry. 2006;188:313-320.

101. Bauer M, et al. Areas of uncertainties and unmet needs in bipolar disorders. Lancet Psychiatry. 2018;5(11):930-939.
102. Hirschfeld RM, et al. Screening for bipolar disorder in patients treated for depression in a family medicine clinic. J Am Board Fam Pract. 2005;18(4):233-239.
103. Forty L, et al. Identifying hypomanic features in major depressive disorder using the hypomania checklist (HCL-32). J Affect Disord. 2009;114(1-3):68-73.
104. Smith DJ, et al. Unrecognised bipolar disorder in primary care patients with depression. Br J Psychiatry. 2011;199(1):49-56.
105. Pini S, et al. Prevalence and 12-month prevalence of bipolar spectrum disorder in Europe. Eur Neuropsychopharmacol. 2005;15(4):425-434.
106. Kessler RC, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry. 2007;64(5):543-552.
107. Suppes T, et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry. 2005;66(7):870-886.
108. Fountoulakis KN, et al. The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for bipolar disorder in adults. Int J Neuropsychopharmacol. 2017;20(2):98-120.
109. Geddes JR, Goodwin GM. Bipolar disorder: clinical uncertainty, evidence-based medicine and large-scale randomised trials. Br J Psychiatry Suppl. 2001;41:s191-194.
110. Cipriani A, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet. 2011;378(9799):1306-1315.
111. Yildiz A, et al. Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Neuropsychopharmacology. 2011;36(2):375-389.
112. Vieta E, et al. Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol. 2011;14(8):1029-1049.
113. Berk M, et al. Stage managing bipolar disorder. Bipolar Disord. 2014;16(5):471-477.
114. Carvalho AF, et al. Bipolar disorder. N Engl J Med. 2020;383(1):58-66.
115. McIntyre RS, et al. Bipolar disorders. Lancet. 2020;396(10265):1841-1856.
116. Goldberg JF, Truman CJ. Antidepressant-induced mania: an overview of current controversies. Bipolar Disord. 2003;5(6):407-420.
117. Tondo L, et al. Antidepressant-associated mood-switching and transition from unipolar major depression to bipolar disorder: a review. J Affect Disord. 2010;126(1-2):1-7.
118. Sani G, et al. Mood stabilizers for the treatment of mood-spectrum disorders. Int J Neuropsychopharmacol. 2017;20(11):908-918.
119. Severus E, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet. 2010;375(9712):385-395.
120. Kishi T, et al. Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis. Mol Psychiatry. 2021;26(8):4146-4157.
121. Greil W, et al. Lithium versus carbamazepine in the maintenance treatment of schizoaffective disorder. Eur Arch Psychiatry Clin Neurosci. 1997;247(1):42-50.
122. Bauer MS, et al. Diagnostic criteria for bipolar disorders: a systematic review. Bipolar Disord. 2002;4(2):89-98.
123. Belmaker RH. Bipolar disorder. N Engl J Med. 2004;351(5):476-486.
124. Mansell W, et al. The interpretation of, and responses to, changes in internal states: an integrative cognitive model of mood swings and bipolar disorders. Behav Cogn Psychother. 2007;35(5):515-539.
125. Jones SH, Bentall RP (eds). The Psychology of Bipolar Disorder. Oxford University Press; 2006.
126. Newman CF, et al. Bipolar Disorder: A Cognitive Therapy Approach. American Psychological Association; 2002.
127. Crowe M, et al. Self-management and bipolar disorder: a clinician’s guide. Mental Health Practice. 2012;15(5):20-25.
128. Conell J, et al. Online information seeking by patients with bipolar disorder: results from an international multisite survey. Int J Bipolar Disord. 2016;4(1):17.
129. Hidalgo-Mazzei D, et al. Internet-based psychological interventions for bipolar disorder: review of the present and insights into the future. J Affect Disord. 2015;188:1-13.
130. Sit DK, et al. Adjunctive bright light therapy for bipolar depression: a randomized double-blind placebo-controlled trial. Am J Psychiatry. 2018;175(2):131-139.
131. Sylvia LG, et al. Nutrition, exercise, and wellness treatment in bipolar disorder. Bipolar Disord. 2013;15(3):249-256.
132. Dauphinais DR, et al. Controlled trial of safety and efficacy of bright light therapy vs negative air ions in patients with bipolar depression. Psychiatry Res. 2012;196(1):57-61.
133. Pinho M, et al. The use of photoperiod and light therapy in bipolar disorder. Curr Pharm Des. 2020;26(13):1442-1453.
134. Berk M, et al. Adjunctive aspirin for the treatment of bipolar depression. BMC Psychiatry. 2019;19(1):348.
135. Sarris J, et al. Adjunctive nutraceuticals for depression: a systematic review and meta-analyses. Am J Psychiatry. 2016;173(6):575-587.
136. Murray G, et al. The use of complementary therapies among people with bipolar disorder. J Affect Disord. 2010;126(1-2):149-153.
137. Sachs GS, Thase ME. Bipolar disorder therapeutics: maintenance treatment. Biol Psychiatry. 2000;48(6):573-581.
138. Geller B, et al. Two-year prospective follow-up of children with a prepubertal and early adolescent bipolar disorder phenotype. Am J Psychiatry. 2002;159(6):927-933.
139. Birmaher B, et al. Course and outcome of bipolar spectrum disorder in children and adolescents: a review of the existing literature. Dev Psychopathol. 2006;18(4):1023-1035.
140. Goldstein TR, et al. Suicidal ideation and behavior in adolescents with bipolar disorder. Arch Gen Psychiatry. 2009;66(11):1257-1266.
141. DelBello MP, et al. Twelve-month outcome of adolescents with bipolar disorder following first hospitalization for a manic or mixed episode. Am J Psychiatry. 2007;164(4):582-590.
142. Kowatch RA, et al. Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2005;44(3):213-235.
143. Diler RS, Birmaher B. Atypical Mood Disorders in Children and Adolescents. Cambridge University Press; 2017.
144. Fountoulakis KN, et al. Lithium treatment of bipolar disorder in adults: a systematic review of randomized trials and meta-analyses. Eur Neuropsychopharmacol. 2022;58:100-121.
145. Bauer M, Glenn T. Lithium revisited. Lancet. 2018;391(10128):1569.
146. Malhi GS, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry. 2021;55(1):7-117.
147. Schatzberg AF, et al. Manual of Clinical Psychopharmacology. 9th ed. American Psychiatric Publishing; 2019.
148. Stahl SM. Stahl’s Essential Psychopharmacology. 5th ed. Cambridge University Press; 2021.
149. National Institute for Health and Care Excellence. Bipolar disorder: assessment and management (CG185). NICE. 2014, updated 2020.
150. International Society for Bipolar Disorders. About ISBD. ISBD. 2024.

This page is for educational purposes only and does not replace professional medical or mental-health advice. Bipolar treatment requires psychiatric supervision. If you are in crisis, call 988 (US/Canada) immediately.